2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Management of attention deficit/hyperactivity disorder and the use of stimulants in prison. Evaluation of the risks and benefits Translated title: Manejo del trastorno por déficit de atención con o sin hiperactividad y empleo de fármacos psicoestimulantes en el medio penitenciario. Evaluación de riesgo y beneficios

      letter
      Revista Española de Sanidad Penitenciaria
      Sociedad Española de Sanidad Penitenciaria

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Attention deficit/hyperactivity disorder (ADHD) is a major focus of interest for prison psychiatry, given its high prevalence in prisons. Most authors conclude that the risk of presenting this disorder may up to ten times higher amongst inmates than among the general public 1 , 2 . Many studies state that there is a higher risk of offences and violent crimes being committed by people suffering from this disorder. Therefore, ADHD is very closely linked to an increase of high risk behaviours, court summonses and prison sentences 3 , 4 . Adequate management of ADHD could improve participation in social rehabilitation and/or educational programs, and reduce the frequency of violent behaviour. This in turn would improve general security for the inmates themselves and for prison staff 5 . Most experts agree on the clear benefits to be had from pharmacological therapy applied to this type of patient in the community. However research and guidance about the identification and management of ADHD among prison inmates are relatively scarce 6 . One of the most effective therapeutic options for treating ADHD is stimulants, which entail a major risk of abuse or trafficking in prison 7 . These drugs are generally well tolerated and present few side effects. However, any prescription should be accompanied by a rigorous diagnosis of the disorder, given the potential risks of abuse presented by some of them 8 . Despite their proven effectiveness, there is considerable resistance to the use of such drugs in prisons worldwide. Given that these drugs stimulate the reward circuits, there is a potential risk of abuse and dependence. This concern is increased because of the high percentage of substance addicts amongst prisoners in general, and among those with a diagnosis of ADHD in particular 9 , 10 . Another factor to be borne in mind is the potential for their use outside the field of prescribed medicines. In most prisons, psychoactive medication is seen as a product that can be sold, bought and exchanged, and the existence of any medication with the potential for abuse in prisons can increase the risk of intimidation, conflict and violence, both for inmates and for healthcare personnel and prison staff 11 . On the other hand, the administration of these drugs often involves treatment directly observed by the team (doctors, nurses, prison staff), which increases costs and reduces the inmate’s autonomy. Therefore, the potential for abuse of these drugs in the prison environment is a challenge and a cause for particular concern for doctors who prescribe them 12 . The experience acquired after work carried out at a number of prisons in Spain and abroad shows that use of stimulants is in most cases a cause for controversy. In my opinion, this is due to the complex nature of such a specific psychiatric diagnosis and the lack of familiarity on the primary care doctor’s part on how to manage this disorder, despite its high prevalence in prisons (over 25% according to the latest literature) 13 . We professionals should be able to correctly diagnose and treat inmates who present this disorder, avoiding the violence, trafficking and abuse of such drugs, which are regarded as narcotics in many countries and much sought after by prisoners 14 . Maybe now is the time to consider the implementation of alternative approaches, such as psychotherapeutic or socio-educational interventions, or the use of drugs with a reduced potential for addiction. In any case, I believe that it is imperative to re-launch a debate on the importance of prescribing these drugs in the prison setting. As prison doctors, we should encourage the exchange of experiences between professionals from different prisons, increase awareness of certain psychiatric disorders and of the challenges posed by some types of prescriptions. Deeper reflection about the risks and benefits offered by stimulants in prison should be the basis for adequate, safe and decisive practices that can establish risk-free guidelines for prescriptions.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Underdiagnosis of Attention-Deficit/Hyperactivity Disorder in Adult Patients: A Review of the Literature

          Objective: To raise awareness of attention-deficit/hyperactivity disorder (ADHD) as an underdiagnosed, undertreated, often comorbid, and debilitating condition in adults. Data Sources: PubMed was searched using combinations of keywords, including ADHD, adult, diagnosis, identify, prevalence, and comorbid, to find articles published between 1976 and 2013. Study Selection: In total, 99 articles were selected for inclusion on the basis of their relevance to the objective and importance to and representation of ADHD research, including international guidelines for adults with ADHD. Results: In a large proportion of children with ADHD, symptoms persist into adulthood. However, although adults with ADHD often experience chaotic lifestyles, with impaired educational and vocational achievement and higher risks of substance abuse and imprisonment, many remain undiagnosed and/or untreated. ADHD is usually accompanied by other psychiatric comorbidities (such as major depressive disorder, anxiety disorder, and alcohol abuse). Indeed, adults with ADHD are more likely to present to a psychiatric clinic for treatment of their comorbid disorders than for ADHD, and their ADHD symptoms are often mistaken for those of their comorbidities. Untreated ADHD in adults with psychiatric comorbidities leads to poor clinical and functional outcomes for the patient even if comorbidities are treated. Effective treatment of adults’ ADHD improves symptoms, emotional lability, and patient functioning, often leading to favorable outcomes (eg, safer driving, reduced criminality). A few medications have now been approved for use in adults with ADHD, while a multimodal approach involving psychotherapy has also shown promising results. Conclusions General psychiatrists should familiarize themselves with the symptoms of ADHD in adults in order to diagnose and manage ADHD and comorbidities appropriately in these patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta-Analysis

            Background: Previous studies have reported a high prevalence of attention deficit hyperactivity disorder (ADHD) among people living in detention (PLD) corresponding to a five- to ten-fold increase compared to the general population. Our main study objective was to provide an updated ADHD prevalence rate for PLD, including PLD in psychiatric units. Sub-objectives included (i) comparing different ways of assessing ADHD, including DSM-5 criteria and (ii) identifying which types of PLD are more likely to have ADHD. Methods: We conducted a systematic review and meta-analysis following the PRISMA guidelines and the MOOSE checklist. PubMed/Medline, PsycINFO, and Web of Sciences were searched combining “ADHD” and “prison” keywords and synonyms for articles published between January 1, 1966 and January 2, 2018. Potential sources of variation to the meta-analytic ADHD prevalence rate were investigated using meta-regressions and subgroups analyses. Results: The meta-analysis pooled 102 original studies including 69,997 participants. The adult ADHD prevalence rate was 26.2% (95% confidence interval: 22.7–29.6). Retrospective assessments of ADHD in childhood were associated with an increased prevalence estimate (41.1, 95% confidence interval: 34.9–47.2, p < 0.001). There was no significant difference in the prevalence estimate between screenings and clinical interviews in adulthood. Only three studies used the DSM-5 definition of ADHD and results were non-significantly different with other DSM versions. We found no difference according to participants' characteristics. Conclusion: Our results confirmed the high prevalence rate of ADHD among PLD, corresponding to a five-fold increase compared to the general population. In light of such high ADHD prevalence, our results reinforce the importance of addressing this critical public health issue by (i) systematically offering ADHD screening and diagnosis to all individuals entering detention, and (ii) delivering treatment, monitoring, and care for ADHD during and after detention. These strategies may help reduce recidivism and reincarceration, as well as violence in detention settings, in addition to improving the health and wellbeing of people living in detention. Additionally, our study suggests that using screening scales may be a reliable way of assessing ADHD, although caution is needed because a complete evaluation by an experienced clinician is required to provide a formal diagnosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

              Medication for the treatment of attention-deficit hyperactivity disorder (ADHD) is in widespread use globally. There is considerable data suggesting that overall, the adverse effect burden from this use is dose dependent and is in the mild to moderate category, but few comprehensive reviews exist of the epidemiology of adverse effects alone. This review provides a general and systems-specific summary of the scientific literature regarding adverse effect data for the drugs in general use for the treatment of ADHD. Although several areas lack definitive data, current evidence suggests that, for the majority of those treated for ADHD, the medications currently available pose little in the way of risk of significant harm. Epidemiological data suggest a low incidence of serious adverse effects, whilst the less serious adverse effects, such as insomnia and anorexia, are relatively common. Also, some specific areas of study suggest lower risks of harm than previously thought, e.g. tic disorders and seizures. However, pre-existing conditions and other interindividual differences may raise the risk of harmful adverse effects, which adds emphasis to the need for careful pretreatment assessment and monitoring. Potential but unlikely long-term treatment effects need to be investigated as carefully as possible, particularly with regard to cardiac sequelae and carcinogenesis. There are both overlaps and differences between the adverse effects of stimulants and nonstimulants, such as atomoxetine. For example, the latter shares the stimulant group's potential for changing cardiovascular parameters, but may not cause insomnia.
                Bookmark

                Author and article information

                Journal
                Rev Esp Sanid Penit
                Rev Esp Sanid Penit
                sanipe
                Revista Española de Sanidad Penitenciaria
                Sociedad Española de Sanidad Penitenciaria
                1575-0620
                2013-6463
                May-Aug 2019
                31 July 2019
                : 21
                : 2
                : 113-114
                Affiliations
                [1] originalChamp-Dollon Prison. Puplinge. Prison Medical Service. University Hospitals of Geneva. Switzerland. University of Valencia. Spain. normalizedUniversidad Católica de Valencia orgnameUniversity of Valencia Spain
                Author notes
                Correspondence: Ana Fructuoso. E-mail: afrucas@ 123456gmail.com
                Article
                00008
                10.4321/S1575-06202019000200008
                6813661
                31642863
                3b3b6354-a3fb-4601-92ad-90a420838fdc

                This is an open-access article distributed under the terms of the Creative Commons Attribution License

                History
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 14, Pages: 02
                Categories
                Letters to the Editor

                Comments

                Comment on this article